RZLT

Rezolute, Inc.

Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001509261 Biotech & Drug Discovery

$4.11 +0.29 (+7.59%)

Oct 27 4:00 PM ET · prev $3.82

Market cap

$372.9M

Small cap

Consensus

Buy

88% Buy or better · 17 analysts

Median target

$10.00

+143% · range $6.00–15.00

Next earnings

Nov 4

in 8 days · EPS est. −$0.18

1 year

−56.7%

from $9.49 · Oct 28

30 days

−1.7%

from $4.18

52-week range

$1.40–10.94

−62% from high · low Dec 11

Avg volume 20D

1.68M

shares / day

Short interest

19.17M

≈19.8% of shares · +14.7%

Days to cover

10.1

at average volume

Insider net

+$28.5K

1 buyer · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

SecBot read BEARISH 5 reports · 90 days

Balance 2 bearish · 0 bullish · 1 mixed · 2 neutral oldest → newest, height = score

Avg score

·High conf. 4/5 ·Next Earnings date, Nov 4, 2026

Strongest NEUTRAL Rezolute filed its definitive proxy statement for the 2027 Annual Meeting, seeking shareholder approval for…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Mar 30 1 insider buy $28.5K at $2.85
R May 12 Rezolute reported Q3 FY2026 EPS of -$0.16 (GAAP), a 30.5% miss vs co…
R Jun 2 Rezolute announced positive interim data from its Phase 3 upLIFT stu…
E Sep 24 Earnings: RZLT Q4 2026 Earnings: EPS $-0.2 (-32.5% vs est)
R Sep 24 Rezolute reported Q4 FY2026 results with a net loss of $20.5M ($-0.2…
R Sep 24 Rezolute reported Q4 FY2026 EPS of -$0.20, a 42.9% miss vs consensus…
R Oct 5 Rezolute announced that the FDA recommended a pre-BLA meeting as a p…
A Oct 6 Cantor Fitzgerald upgrades

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $28.5K at an average $2.85. No open-market sales. Price is 44% above their cost.
InstitutionsBULLISH

Q2 2026: 25 added (0 new), 11 trimmed or exited.
AnalystsBULLISH

15 of 17 rate it Buy or better. Every target is above the price.
EstimatesFALLING

Current-quarter EPS estimate −$0.146 → −$0.185 over 90 days. 0 up, 4 down in 30 days.
Short sellersSTEADY

Short interest +14.7% to 19.17M shares. 10.1 days to cover, ≈19.8% of shares.
TrendDOWNTREND

4% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
JACOBS LEVY EQUITY MANAGEMENT, INC	DOUBLED	2,561,654	$13.3M
JENNISON ASSOCIATES LLC	TRIM	2,459,308	$12.8M
MORGAN STANLEY	TRIM	1,618,783	$8.4M
VANGUARD PORTFOLIO MANAGEMENT LLC	TRIM	1,380,746	$7.2M
GOLDMAN SACHS GROUP INC	DOUBLED	1,316,782	$6.8M
Nuveen, LLC	DOUBLED	1,295,209	$6.7M
DIMENSIONAL FUND ADVISORS LP	ADD	890,733	$4.6M
BANK OF AMERICA CORP /DE/	NEAR_EXIT	730,332	$3.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts

Buy 88% rate it Buy or better

Strong Buy6Buy9Hold2Sell0Strong Sell0

12-month targets · 10 analysts

$4.11 $6.00 $10.00 $15.00

Price is below the lowest target. Median implies +143%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Oct 6, 2026	Lake Street MAINTAIN	MAINTAIN	Buy
Oct 6, 2026	Citizens MAINTAIN	MAINTAIN	Market Outperform
Oct 6, 2026	Cantor Fitzgerald UPGRADE	UPGRADE	Overweight
Sep 30, 2026	Lake Street INITIATE	INITIATE	Buy
Sep 29, 2026	Craig-Hallum UPGRADE	UPGRADE	Buy
Sep 25, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy

Insider ledger

Form 4

$28.5K

bought · 1 insider

sold · 0 insiders

+44.2%

vs their $2.85 cost

Date	Insider	Type	Value
Oct 21, 2026	Evans Daron CFO	GIFT	16,000 sh
Oct 21, 2026	Evans Daron CFO	GIFT	4,000 sh
Sep 2, 2026	Karnawat Sunil Ratilal Chief Commercial Officer	TAX W/H	$10.2K
Jul 2, 2026	Evans Daron CFO	TAX W/H	$15.3K
Jul 2, 2026	Elam Nevan C CEO	TAX W/H	$39.9K
Jul 2, 2026	ROBERTS BRIAN KENNETH Chief Medical Officer	TAX W/H	$15.3K
Mar 30, 2026	Evans Daron CFO	BUY	$28.5K
Mar 2, 2026	Evans Daron CFO	TAX W/H	$34.2K

Earnings setup

Estimates

Nov 4

reports in 8 days

−$0.18

EPS estimate, this quarter

−27%

estimate change, 90 days

0↑ 4↓

revisions, 30 days

Current-quarter EPS estimate

−$0.146

90d

−$0.146

60d

−$0.146

30d

−$0.185

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.18	-$0.21–-$0.15	-26.7%	$0.00
Next Q	-$0.17	-$0.21–-$0.14	-30.9%	$0.00
Current FY	-$0.70	-$0.84–-$0.57	-11.4%	$2.1M
Next FY	-$0.47	-$0.97–-$0.15	-67.3%	$54.1M

Washington

Corporate Lobbying

13 lobbying filings and 1 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 15, 2026

19,168,429

shares short

+14.7%

vs prior settlement

10.1

days to cover

≈19.8%

of shares outstanding

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 21, 2026 SEC

Rezolute filed its definitive proxy statement for the 2027 Annual Meeting, seeking shareholder approval for seven…

DEF 14A — Impact 5/10

Oct 21, 2026 Insider

Evans Daron gifted 16,000 shares

CFO

Oct 21, 2026 Insider

Evans Daron gifted 4,000 shares

CFO

Oct 15, 2026 Short interest report

Short Interest: RZLT up 15% to 19.2M shares

Settlement 2026-10-15 | Days to cover: 10.08 | ≈19.82% of shares outstanding (est.)

Oct 14, 2026 SEC

Rezolute announced completion of enrollment in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with…

8-K — Impact 5/10

Oct 5, 2026 SEC

Rezolute announced that the FDA recommended a pre-BLA meeting as a precursor to submitting a Biologics License…

8-K — Impact 6/10

Sep 2, 2026 Insider

Karnawat Sunil Ratilal surrendered for taxes 2,267 shares

Chief Commercial Officer @ $4.50 ($10.2K)

Jul 21, 2026 Press

Rezolute announced management participation in the BTIG Virtual Biotechnology Conference on July 28-29, 2026. This is…

Impact 2/10

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 4, 2026

Earnings date

RZLT Q1 2027 Earnings Scheduled — 2026-11-04

Recent

Oct 15, 2026

Short interest

Short Interest: RZLT up 15% to 19.2M shares

Settlement 2026-10-15 | Days to cover: 10.08 | ≈19.82% of shares outstanding (est.)

Oct 5, 2026

Press release

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these…

Sep 24, 2026

Earnings

Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare…

Sep 24, 2026

Earnings result

RZLT Q4 2026 Earnings: EPS $-0.2 (-32.5% vs est)

Sep 15, 2026

Earnings date

RZLT Q4 2026 Earnings After Market Close — 2026-09-15